Full-Time
Largest independent home infusion therapy provider
$21.07 - $35.12/hr
Itasca, IL, USA
In Person
See people who can refer or advise you
Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Norfolk, Virginia
Founded
1979
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Paid Time Off
Bonding Time Off
401(k) Retirement Plan
401(k) Company Match
Health Savings Account/Flexible Spending Account
Flexible Spending Accounts
Tuition Reimbursement
Family Support
Mental Health Support
Company Paid Life Insurance
Award/Recognition Programs
Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.
Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.
Option Care Health shares rose 3.5% after Goldman Sachs initiated coverage with a Neutral rating and a $22 price target, suggesting potential upside from the stock's recent price of $20.51. The move comes after the stock declined 33% over the previous six months. Whilst Goldman Sachs took a cautious stance, other firms including Deutsche Bank and UBS maintain Buy ratings on the stock. The company recently reported weak first-quarter 2026 results, with revenue of $1.35 billion missing forecasts despite a 1.3% year-on-year increase. Option Care Health also lowered its full-year revenue guidance to $5.73 billion, below analyst estimates. The stock is down 35.5% year-to-date and trading 43.2% below its 52-week high.
Option Care Health has appointed Robert Okunski as Vice President of Investor Relations, effective 26 May 2026. He will lead the company's investor relations strategy and serve as primary liaison with the investment community. Okunski brings over 20 years of investor relations experience across healthcare, technology and energy sectors. He joins from Enhabit Home Health & Hospice, where he served as Vice President of Investor Relations, and previously held senior positions at Velo3D, SunPower Corporation, Spansion and PeopleSoft. Option Care Health is the largest independent provider of home and alternate site infusion services in the US, employing over 8,000 staff including more than 5,000 clinicians across all 50 states.
Option Care Health, the largest independent provider of home infusion services in the US, reported Q1 revenues of $1.35 billion, up 1.3% year on year but missing analyst expectations by 3.3%. The company operates 177 locations across 43 states with over 4,500 clinicians. Chief executive John Rademacher acknowledged the "mixed performance" and expressed dissatisfaction with revenue growth momentum. Full-year guidance also fell short of analyst expectations. Across the senior health, home health and hospice sector, seven tracked companies reported a satisfactory Q1, with revenues beating consensus estimates by 0.9% on average. However, Option Care Health posted the weakest performance against analyst estimates despite raising full-year guidance. The stock has fallen 27.1% since reporting, currently trading at $21.59.